Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors

Who May Qualify: - Male or female \>= 18 years of age - Documentation of a diagnosis of brain tumor including brain metastases, any grade of gliomas and meningiomas - The participant is scheduled for standard of care surgical tumor resection - The participant (or legally acceptable representative if applicable) provides written willing to sign a consent form for the trial Who Should NOT Join This Trial: - Male or female \< 18 years of age - Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data - Not medically cleared for surgery - Individuals who cannot tolerate MRI scan or PET/CT scan - Pregnant or breast-feeding women - Serum creatinine OR measured or calculated creatinine clearance (Glomerular filtration rate \[GFR\] can be use in place of creatinine or creatinine clearance \[CrCl\]) =\< 1.5 X institutional upper limit of normal (ULN) OR \>= 60mL/min for subjects with creatinine levels \> 1.5 X institutional ULN - Creatinine clearance should be calculated per institutional standard - Serum total bilirubin: =\< 1.5 X institutional ULN OR direct bilirubin =\< institutional ULN for subjects with total bilirubin levels \> 1.5 institutional ULN - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) =\< 2.5 X institutional ULN OR =\< 5 X institutional ULN for subjects with Gilberts syndrome - Albumin \>= 2.5 mg/dL - Patients with splenic dysfunction or post splenectomy - Any abnormalities that would be a contraindication to gadolinium-based contrast agent Always talk to your doctor about whether this trial is right for you.